A carregar...
Overcoming Resistance of Human Non-Hodgkin’s Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors
Patients with B-cell non-Hodgkin’s lymphoma (B-NHL) who fail to respond to first-line treatment regimens or develop resistance, exhibit poor prognosis. This signifies the need to develop alternative treatment strategies. CD19-chimeric antigen receptor (CAR) T cell-redirected immunotherapy is an attr...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6025421/ https://ncbi.nlm.nih.gov/pubmed/29904021 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10060200 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|